摘要:
The invention relates to a process for the metathesis of two α‑olefin compounds, characterized in that it comprises the use of at least one membrane for extracting ethylene from the reaction medium, said membrane being permeable to gases and impermeable to liquids. The invention relates more particularly to a process for the metathesis of two α‑olefin compounds, carried out in a reaction device comprising two zones separated by said at least one membrane: - a first zone, fed with reactants and catalyst, in which the liquid-phase metathesis reaction is initiated and the liquid reaction medium is circulated in contact with the wall constituted by the membrane, and - a second zone, fed with a gaseous stream that is inert with respect to the membrane and the constituents of the reaction medium of the first zone, optionally under a pressure slightly lower than that in the first zone or in the form of a purge by a gas flow at sufficient flow rate, so as to drive the migration, by diffusion, of the ethylene dissolved in the reaction medium from the first zone to the second zone.
摘要:
In the following, citalopram diol means 4-(4-(dimethylamino)-l-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)-benzonitrile, as free base and/or acid addition salt. The invention relates to a process for the preparation of racemic citalopram diol and/or R- or S-citalopram diol, comprising the separation of a non-racemic mixture of R- and S-citalopram diol with more than 50% of one of the enantiomers into a fraction being enriched with S- or R-citalopram diol and a fraction comprising RS-citalopram diol wherein the ratio of R-citalopram diol:S-citalopram diol is equal to 1:1 or closer to 1:1 than in the initial mixture. The method is characterized in that (i) RS-citalopram diol is precipitated from a solution of the initial non-racemic mixture, or R- or S-citalopram diol is dissolved into a solvent from the initial non-racemic mixture, leaving a residue of RS-citalopram diol, and in that (ii) the residue/precipitate formed is separated from the final solution phase, followed by optional steps of repetition, recrystallisation, purification, isolation and conversion between free base and salts. The invention also relates to a process for the preparation of RS-citalopram, S-citalopram or R-citalopram (all as free base and/or acid addition salt) comprising the method described above followed by ring closure.
摘要:
The invention relates to the field of separation by distillation of 6-aminocapronitrile (ACN) and hexamethylenediamine (HMD) from a mixture comprising ACN, HMD, tetrahydrozaepine (THA), adiponitrile (ADN) and low boilers (LB). A method for producing a distillate stream comprising HMD is disclosed, which is suitable for the production of Nylon-6,6. The tails stream from the distillation of the mixture can be further distilled to produce a distillate comprising ACN and THA, which is particularly suitable for use in the production of caprolactam and Nylon-6 from the caprolactam. Process conditions of the method of the invention disfavor the production of 2-cyanocyclopentylideneimine (CPI).
摘要:
A process for preparing one or more cyano-aliphatic aldehydes is described. The process comprises (a) preparing an olefinically-unsaturated cyano-aliphatic composition via a Diels Alder reaction of a diene and a dienophile composition; (b) contacting in a hydroformylation zone the olefinically-unsaturated cyano-aliphatic composition with carbon monoxide and hydrogen in the presence of a transition metal-organophosphorus ligand complex catalyst under hydroformylation conditions sufficient to prepare a hydroformylation product (c) mixing in an extraction zone the hydroformylation product composition with water under conditions sufficient to obtain by phase separation a nonpolar phase a polar phase comprising water and the one or more cyano-aliphatic aldehydes; (d) separating the one or more cyano-aliphatic aldehyde products from the hydroformylation product composition.
摘要:
The invention relates to novel compound of formula (IV), which is an organic acid salt of N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine ester. This compound is an useful intermediate for process of preparation of Valsartan of formula (I), chemically known as (S)-N-(l-Carboxy-2-methylprop-l-yl)-N-pentanoyl-N-[2'-(lH-tetrazol-5-yl)biphenyl-4- ylmethyl]amine. This invention also relates to a process for preparing Valsartan using novel intermediate of formula (IV).
摘要:
The present invention relates to an improved process for isolation and purification of Entacapone, pharmaceutical compositions and therapeutic uses thereof. The process provides an improved yield and improved isomeric purity of produced Entacapone.